Finally, we assessed the relationship between the 13 IRPGS expression levels and the drug activity of anti-tumor drugs in the NCI-60 cancer cell set and found that, as shown in Figure 11, the sensitivity of nelarabine was increased by GDF10 (Cor = 0.915, p<0.001) and GRAP2 (Cor = 0.855, p<0.001), and the upregulation of GDF10 also enhanced the drug sensitivity of chelerythrine (Cor = 0.617, p<0.001). This evidence concerns the gene GRAP2 and neoplasm.